Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Final trial results from new NSCLC immunotherapy

Patients with Stage IV squamous non-small cell lung cancer enrolled in clinical trial to test the immunotherapy atezolizumab and chemotherapy against chemotherapy alone experienced a longer survival rate, among a subgroup of patients with high PD-LI.

The data for the Impower131 Trial was presented today by Dr. F. Cappuzzo, from Azienda Unità Sanitaria Locale della Romagna, Ravenna/Italy at the IASLC 2019 World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer.

IMpower131 is a randomised Phase III trial of atezolizumab chemotherapy vs chemotherapy alone as first-line therapy in Stage IV squamous NSCLC, which is the most advanced form of the disease.

The five-year survival rate for those diagnosed with stage IV lung cancer is less than 10 percent.

The multi-centre trial enrolled 1021 patients-- the 343 patients in Arm B received atezolizumab carboplatin nab-paclitaxel 100 mg/m2 qw.

There were 340 patients enrolled in Arm C who received carboplatin nab-paclitaxel for four or six cycles followed by best supportive care.

The proportion of patients with high positive or negative PD-L1 expression was similar between arms.

Median overall survival in the Intention to Treat population was 14.2 months in Arm B vs 13.5 months in Arm C not crossing the boundary for statistical significance.

In the PD-L1-high subgroup, median overall survival was 23.4 vs 10.2 months, respectively.

Treatment-related Grade 3-4 AEs and treatment-related adverse effects occurred in 68.0% and 21.0% (Arm B) and 57.5% and 10.5% (Arm C) of patients; no new safety signals were identified, consistent with previous analyses.

Final overall survival in Arm B vs C did not cross the boundary for statistical significance but clinically meaningful overall survival improvement was observed in the PD-L1-high subgroup, despite not being formally tested.

"The study provides additional evidence on the efficacy of immunotherapy in patients with lung cancer. The strong benefit observed in high PD-L1 expressors highlights relevance of biomarkers for patient selection," Dr. Cappuzzo said.

Source: The International Association for the Study of Lung Cancer

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation